MARKET

PYXS

PYXS

Pyxis Oncology, Inc.
NASDAQ
2.280
+0.070
+3.17%
After Hours: 2.260 -0.02 -0.88% 19:13 05/15 EDT
OPEN
2.210
PREV CLOSE
2.210
HIGH
2.350
LOW
1.950
VOLUME
986.70K
TURNOVER
--
52 WEEK HIGH
5.55
52 WEEK LOW
0.9700
MARKET CAP
143.31M
P/E (TTM)
-1.7510
1D
5D
1M
3M
1Y
5Y
1D
Pyxis Oncology (PYXS) Cash Runway Under One Year Reinforces Bearish Funding Narratives
Simply Wall St · 14h ago
Analysts Conflicted on These Healthcare Names: Aquestive Therapeutics (AQST), Pyxis Oncology (PYXS) and Biogen (BIIB)
TipRanks · 1d ago
RBC Capital Keeps Their Buy Rating on Pyxis Oncology (PYXS)
TipRanks · 1d ago
Pyxis Oncology (PYXS) Gets a Buy from Guggenheim
TipRanks · 1d ago
Analysts Have Conflicting Sentiments on These Healthcare Companies: Humana (HUM), Pyxis Oncology (PYXS) and Candel Therapeutics (CADL)
TipRanks · 1d ago
Pyxis Oncology Faces Urgent Capital Needs and Potential Dilution Risks Amid Market Volatility
TipRanks · 1d ago
Pyxis Oncology Shares Slide on Steeper 1Q Loss
Dow Jones · 1d ago
Analysts Offer Insights on Healthcare Companies: Pyxis Oncology (PYXS) and Journey Medical Corp (DERM)
TipRanks · 2d ago
More
About PYXS
Pyxis Oncology, Inc. is a clinical-stage company focused on developing therapeutics to target difficult-to-treat cancers. The Company is building therapeutics that hold the potential for mono and combination therapies. Its clinical program portfolio includes micvotobart pelidotin (MICVO), PYX-106, Sotigalimab (PYX-107), PYX-203, PYX-102, and APX601. The Company’s lead product candidate, MICVO, is an antibody-drug conjugate (ADC) that targets Extradomain-B Fibronectin (EDB+FN), a non-cellular structural component of the tumor extra-cellular matrix (ECM). MICVO is designed to generate a multi-pronged attack on difficult-to-treat cancers by directly killing cancer cells, reducing ECM density, inhibiting tumor angiogenesis and mobilizing an anti-tumor immune response. The Company’s ADC, MICVO, consists of human Immunoglobulin G1 (IgG1) and is site-specifically conjugated with a cleavable linker and a microtubule inhibitor (optimized auristatin) payload.

Webull offers Pyxis Oncology Inc stock information, including NASDAQ: PYXS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PYXS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PYXS stock methods without spending real money on the virtual paper trading platform.